All Pharma News
Treatment with RYBREVANT and Lazertinib Showed Survival in Advanced NSCLC

Treatment with RYBREVANT and Lazertinib Showed Survival in Advanced NSCLC
PR NEWSWIRE
11 Sep 2023
Share Share
Janssen Submits MAA to the EMA Seeking Approval of Erdafitinib

Janssen Submits MAA to the EMA Seeking Approval of Erdafitinib
GLOBENEWSWIRE
08 Sep 2023
Share Share
Janssen Submits sNDA to the USFDA Seeking Full Approval of BALVERSA for MUC

Janssen Submits sNDA to the USFDA Seeking Full Approval of BALVERSA for MUC
PR NEWSWIRE
28 Aug 2023
Share Share
Janssen submits sBLA to FDA for NSCLC combination therapy

Janssen submits sBLA to FDA for NSCLC combination therapy
PHARMACEUTICAL TECHNOLOGY
28 Aug 2023
Share Share
Janssen Submits sBLA to FDA Seeking Approval of RYBREVANT for NSCLC

Janssen Submits sBLA to FDA Seeking Approval of RYBREVANT for NSCLC
PR NEWSWIRE
25 Aug 2023
Share Share
J&J`s Janssen to close part of its vaccine division

J&J`s Janssen to close part of its vaccine division
REUTERS
24 Aug 2023
Share Share
EC grants CMA to Janssen`s Talvey for multiple myeloma

EC grants CMA to Janssen`s Talvey for multiple myeloma
PRESS RELEASE
23 Aug 2023
Share Share
Alkermes` $194M payment from Janssen gets approval from court

Alkermes` $194M payment from Janssen gets approval from court
Tyler Patchen ENDPTS
21 Aug 2023
Share Share
EC Approves Reduced Dosing Frequency for Janssen™s Bispecific Antibody TECVAYLI

EC Approves Reduced Dosing Frequency for Janssen™s Bispecific Antibody TECVAYLI
GLOBENEWSWIRE
18 Aug 2023
Share Share
FDA approves J&J`s PARP combo drug Akeega for prostate cancer

FDA approves J&J`s PARP combo drug Akeega for prostate cancer
FDA
12 Aug 2023
Share Share